Rosalind J Carter

Dados Biográficos

ID6059149
NOMERosalind J Carter
PRENOMESRosalind J
SOBRENOMECarter
ASSINATURACARTER R J
AFILIAÇÕESChi-Chi N. Udeagu Pratt, Rosalind J. Carter, and Marcelle C. Layton are with the Communicable Disease Program, New York City Department of Health, New York, NY. Denise Paone is with the Chemical Dependency Institute, Beth Israel Medical Center, New York, NY.
ORCID0000-0003-2917-5827
VERIFICADOSim
TOTAL DE OBRAS4
TOTAL DE CITAÇÕES0
TOTAL COMO AUTOR4
TOTAL COMO EDITOR0
PRIMEIRO ANO DE PUBLICAÇÃO2002
ANO MAIS RECENTE DE PUBLICAÇÃO2023
ÍNDICE H0

  • Public perceptions of Ebola vaccines and confidence in health services to treat Ebola, malaria, and tuberculosis

    Open AccessAybüke Koyuncu, Rosalind J Carter et al.ARTICLEPLOS Global Public Health2023

    Uganda used Ebola vaccines as part of its preparedness and response during the 2018–2020 10 th Ebola virus disease (EVD) outbreak in neighboring Democratic Republic of the Congo (DRC). We evaluated the public’s perceptions of Ebola vaccines and compared their confidence in health services to treat Ebola versus malaria and tuberculosis as part of a survey on Ebola knowledge, attitudes, and practices (KAP) conducted in March 2020. A cross-sectional…

  • Uganda’s experience in Ebola virus disease outbreak preparedness, 2018–2019

    Open AccessJane Ruth Aceng, Alex Riolexus Ario et al.ARTICLEGlobalization and Health2020

    BACKGROUND: Since the declaration of the 10th Ebola Virus Disease (EVD) outbreak in DRC on 1st Aug 2018, several neighboring countries have been developing and implementing preparedness efforts to prevent EVD cross-border transmission to enable timely detection, investigation, and response in the event of a confirmed EVD outbreak in the country. We describe Uganda's experience in EVD preparedness. RESULTS: On 4 August 2018, the Uganda Ministry of…

  • Comparing two service delivery models for the prevention of mother-to-child transmission (PMTCT) of HIV during transition from single-dose nevirapine to multi-drug antiretroviral regimens

    Open AccessLandry Tsague, Fatima Tsiouris et al.ARTICLEBMC Public Health2010

    All sites successfully transitioned from sd-nvp to md-ARV regimens for PMTCT. Full package sites offer the most efficient model for providing immunological assessment and enrollment into care and treatment of HIV+ pregnant women. Strengthening the capacity of stand-alone PMTCT sites to achieve the same objectives is paramount

  • Hepatitis C Screening and Management Practices

    Chi-Chi N Udeagu Pratt, Denise Paone et al.ARTICLEAmerican Journal of Public Health2002Referências: 14

    Injection drug users (IDUs) account for more than 60% of all new hepatitis C virus (HCV) infections in the United States.1,2 Fifty to eighty percent of new IDUs are infected within 6 to 12 months of initial injection.3 Current treatment regimens are not highly effective, and no vaccine against HCV is available.1,4–7 Studies suggest that drug treatment and syringe exchange programs may play a role in reducing HCV infection among participants by pr…